Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Mol Cancer Res. 2019 Mar 12;17(6):1391–1402. doi: 10.1158/1541-7786.MCR-18-0763

Figure 1. E-cadherin upregulation is prognostic for improved outcomes in sarcoma.

Figure 1.

A-B. Osteosarcomas with elevated E-cadherin have better metastasis-free survival (A) and overall survival (B) as compared to tumors with low/no E-cadherin expression. C-D. Soft tissue sarcomas (STS) from The Cancer Genome Atlas with higher E-cadherin mRNA (C) and protein expression (D) have improved overall survival as compared to tumors with low or no E-cadherin.